MBX (MBX) Stock Price & Analysis
MBX (MBX) rose 0.49% to USD 61.72 as of September 8, 2026 at 05:45 UTC, according to Nexqual real-time market data.
MBX last closed at USD 61.72; the session ranged USD 60.6–62.73 on volume of 271,775 shares. Market capitalization is —, with a 52-week range of USD 9.63–72.64 (NMS). Source: Nexqual, September 8, 2026 at 05:45 UTC.
Key Statistics (as of September 8, 2026 at 05:45 UTC)
| Price | USD 61.72 |
|---|---|
| Change | ▲ 0.49% (up) |
| Previous Close | USD 61.72 |
| Open | USD 61.72 |
| Day Range | USD 60.6 – 62.73 |
| 52-Week Range | USD 9.63 – 72.64 |
| Volume | 271,775 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (MBX)
Nexqual's technical model rates MBX "SELL" based on 1 bullish and 4 bearish signals across 128 daily candles, as of September 8, 2026 at 05:45 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 44.65 (neutral) |
| vs SMA50 | Below (USD 62.99) |
| MACD | -0.26 (negative) |
From MBX's Latest SEC 10-K Filing (filed 2026-03-12)
Source: SEC EDGAR 10-K. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RAPP | Rapport Therapeutics, Inc. | USD 45.77 | ▼ 6% |
| BCAX | Bicara Therapeutics Inc. | USD 23.17 | ▼ 1.66% |
| ZBIO | Zenas BioPharma, Inc. | USD 32.88 | ▼ 0.75% |
| ALMS | Alumis Inc. | USD 11.1 | ▲ 7.25% |
| MLYS | Mineralys Therapeutics, Inc. | USD 28.21 | ▼ 2.86% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:45 UTC. This page is informational and not investment advice.